Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled induction study of RO7790121 in moderately to severely active Crohn's disease
CTR20250426Phase 3Active
- Sponsor
- Roche
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of afimkibart in Crohn's disease, sponsored by Roche. Started May 2025; status: active.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20250426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250426.